期刊文献+

山楂叶总黄酮双层缓释片的研制

Development of sustained release bilayer tablets of total flavonoids from hawthorn leaves
下载PDF
导出
摘要 目的山楂叶总黄酮双层缓释片的制备研究。方法双层缓释片由速释层和缓释层两部分组成。以释放度为考察指标,考察不同种类的辅料及其用量,确定最佳处方。结果山楂叶总黄酮双层缓释片质量稳定,其最优处方为速释层:3.2%山楂叶提取物,22%MCC,1.1%c CMC-Na(内加),2.1%c CMC-Na(外加),11.2%淀粉,0.4%硬脂酸镁;缓释层:16%山楂叶提取物,24%HPMCK4M,3%CMC-Na,16.4%MCC,0.6%硬脂酸镁。结论山楂叶总黄酮双层缓释片处方合理,质量可控,是值得开发的产品。 Objective To screen the optimal formula for sustained release bilayer tablet of total flavonoids. Methods Sustained release bilayer tablet consists of a rapid release layer and a slow release layer. Different kinds of excipients in the formulation were selected and their dosage was optimized by examining the dissolution rate. Results The optimal formulation was as follows: the rapid release layer contained 3. 2% total flavonoid extracts of hawthorn leaves,22% of MCC,1. 1% of c CMC- Na( add within),2. 1% of c CMC- Na( plus),11. 2% of starch,and0. 6% of magnesium stearate,while the slow release layer contained16% of hawthorn leaves total flavonoids,24% of HPMCK4 M,3% of CMC- Na,16. 4% of MCC,and 0. 6% of magnesium stearate. Conclusion The as- prepared sustained release bilayer tablet is a promising formulation with reliable therapeutic effects.
出处 《时珍国医国药》 CAS CSCD 北大核心 2016年第7期1641-1643,共3页 Lishizhen Medicine and Materia Medica Research
基金 贵州省中药现代化科技产业研究开发专项[黔科合社字(2008)5024号] 贵州省中药现代化专项[黔科合中药字【2012】5040号]
关键词 山楂叶总黄酮 双层缓释片 制备 释放度 Hawthorn leaves total flavonoids Sustained release bilayer tablets Preparation Release rate
  • 相关文献

参考文献6

二级参考文献26

  • 1邓汉武.大鼠心肌缺血再灌注损伤实验法[J].中国药理学通报,1989,5(5). 被引量:76
  • 2于瑞敏.抗氧化剂与动脉粥样硬化[J].中国动脉硬化杂志,1995,3(3):267-270. 被引量:2
  • 3黄沛力,曾昭晖.银杏叶和山楂叶的抗氧化作用[J].中国药学杂志,1996,31(5):274-276. 被引量:50
  • 4董英杰,张乃先,张明磊,戴宝合.大果山楂叶黄酮成分研究[J].沈阳药科大学学报,1996,13(1):31-33. 被引量:45
  • 5许正斌 高奎斌 等.山楂叶综述[J].中医药学报,1985,(4):49-49.
  • 6叶希韵 康惠珠 程容懿 等.山楂叶总黄酮对实验性动脉粥样硬化鹌鹑脏器的保护研究[J].上海师范大学学报:自然科学版,2001,12:48-52.
  • 7Giovamni Diminno, Melvin J, Silver. Mouse antithromobotic assay:A simple method for the evaluation of antithromobotic agents in vivo. potentiation of antithromobotic activity by ethyl alohol [ J ]. The Journal of Pharmacology and Experiment Therapeutics, 1983,225 ( 1 ) :57.
  • 8Haberland M, Fogdman AM. The role of altered lipoproteins in the pathogenesis of atherosclerosis [J ]. Amer Heart J, 1987, 113: 573-586.
  • 9Scott MG. Cholesterol and coronary heart disease -the 21th century[J]. Arch Intern Med, 1997, 157: 177-184.
  • 10Steinberg D. Cholesterol and cardiovascular disease: Lipoprotein and pathogenesis of atherosclerosis[J ]. Circulation, 1987, 76(3): 508-514.

共引文献137

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部